Good luck with the product! Much of the success for optimal formulary placement of this drug came at the expense of Zyclara, a product owned by a different pharmaceutical concern. A true conflict of interest - Ken Baker was responsible for negotiating deals for both drugs, and he sold out Zyclara in order to get better deals for Duexis. He would have kept the gig going, but he got caught in his own game.
So Ken Baker was working for Graceway and representing Horizon at the same time in front of customers?
